Relay Therapeutics hits VC jackpot with $400M Series C round for protein motion drug discovery
The round, led by SoftBank Vision Fund, is more than six times the size of Relay's Series B round, which it closed in December 2017.
The round, led by SoftBank Vision Fund, is more than six times the size of Relay's Series B round, which it closed in December 2017.
The company will use funding to bring cell therapies into clinic in oncology and autoimmune indications.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The tech giant is applying its AI expertise to the medical space. But that's not all — Google has also shown interest in other healthcare topics like interoperability and insurance.
Mountain View, California-based DNAnexus has closed a $58 million financing round led by Foresite Capital. Microsoft, TPG Biotech, WuXi NextCODE, GV (formerly Google Ventures), MidCap Financial and Claremont Creek Ventures also participated.
Fractyl Laboratories has raised a $44 million Series D financing round to build upon a chance discovery that bariatric surgery can resolve Type 2 diabetes in a subset of patients — independent of any weight loss.
New research by the Cancer Research Institute puts the number of industry-wide combination trials at 1,105.
Evelo Biosciences is doing pretty well for a preclinical company in an exploratory field. The 2014 startup has already executed a merger and raised $100 million in venture financing for its so-called "monoclonal microbials."
Healthcare investments hit $3.8 billion in the second quarter of 2017, marking a spike in these deals and a milestone for the healthcare industry in general, according to StartUp Health's half year report.
Former Google Ventures (GV) CEO Bill Maris is reportedly about to close on a $100 million San Diego-based venture fund, for which he is the sole investor. The catch? This story has played out before.
Bill Maris, who cofounded GV (formerly Google Ventures) and led the firm from 2009 until earlier this year, is rumored to be setting up shop in San Diego with a new $230 million healthcare fund.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Krishna Yeshwant, the part-time physician who leads GV's (formerly Google Ventures) life sciences and health investment team, discusses the kind of consumer wearable company that would win its support.
AstraZeneca joins other notable investors like GV (Google Ventures) and Novartis to fund Rani Therapeutics' oral biologics.
Forty Seven has licensed more than 100 patents from Stanford University that are related to the company's lead therapeutic, monoclonal antibody Hu5F9-G4, as well as a number of novel immune checkpoint inhibitors and cancer-specific antibodies.